(Q53100434)

11 May 2018

editorial

0 references

title

Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men - a suggested update. (English)

1 reference

11 May 2018

1 reference

Bruno Lunenfeld

1

1 reference

11 May 2018

George Mskhalaya

series ordinal

2

1 reference

11 May 2018

Svetlana Kalinchenko

series ordinal

3

1 reference

11 May 2018

Yulia Tishova

series ordinal

4

1 reference

11 May 2018

publication date

4 November 2013

1 reference

11 May 2018

published in

The Aging Male

1 reference

11 May 2018

volume

16

1 reference

11 May 2018

issue

4

1 reference

11 May 2018

page(s)

143-150

1 reference

11 May 2018

International web survey shows high prevalence of symptomatic testosterone deficiency in men.

cites work

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Comparison of screening questionnaires for the diagnosis of hypogonadism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Clinical assessment and validation of an Arabic Aging Male Symptoms questionnaire in patients with androgen deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Association between lower urinary tract symptoms and sexual dysfunction assessed using the core lower urinary tract symptom score and International Index of Erectile Function-5 questionnaires.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Acanthosis nigricans associated with insulin resistance : pathophysiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Testosterone, cardiovascular disease and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

How to help the aging male? Current approaches to hypogonadism in primary care.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Identification of late-onset hypogonadism in middle-aged and elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Symptoms of testosterone deficiency in early middle aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Androgen deprivation therapy: monitoring and managing the complications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Emerging cardiometabolic complications of androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Testosterone treatment and mortality in men with low testosterone levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Testosterone therapy and mortality in US veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Caveat emptor: does testosterone treatment reduce mortality in men?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Effect of vitamin D supplementation on testosterone levels in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Sex steroids and mortality in men referred for coronary angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

An approach for development of age-, gender-, and ethnicity-specific thyrotropin reference limits

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Endocrine consequences of opioid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Pituitary radiographic abnormalities and clinical correlates of hypogonadism in elderly males presenting with erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

A critical evaluation of simple methods for the estimation of free testosterone in serum.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Change in testosterone concentrations over time is a better predictor than the actual concentrations for symptoms of late onset hypogonadism.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Testosterone levels and psychological health status in men from a general population: the Tromsø study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Onset of effects of testosterone treatment and time span until maximum effects are achieved

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Free testosterone levels are associated with mobility limitation and physical performance in community-dwelling men: the Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

FRAX and its applications to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Osteoporosis in men: an Endocrine Society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Endogenous testosterone levels, physical performance, and fall risk in older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Effects of testosterone on sexual function in men: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

The triad of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome: findings from a multi-ethnic Asian men study (The Subang Men's Health Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Is low testosterone concentration a risk factor for metabolic syndrome in healthy middle-aged men?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Low testosterone level is an independent determinant of endothelial dysfunction in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Endogenous sex hormones and progression of carotid atherosclerosis in elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Testosterone and depression: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

The hormonal pathway to cognitive impairment in older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Thinking with your gonads: testosterone and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

The “Aging Males’ Symptoms” Scale (AMS): predictive value for lowered circulating androgens

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F13685538.2013.853731

10.3109/13685538.2013.853731

21 January 2018

Identifiers

DOI

1 reference

11 May 2018

1 reference

11 May 2018